A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor
Open Access
- 1 January 2016
- journal article
- case report
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 152 (1), 106-3
- https://doi.org/10.1001/jamadermatol.2015.2705
Abstract
Case Report from JAMA Dermatology — A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 InhibitorKeywords
This publication has 1 reference indexed in Scilit:
- Faculty Opinions recommendation of Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.Published by H1 Connect ,2016